Mary D. Stephenson

Mary D. Stephenson

Auto-generated profile, based on publicly available information

Mary D. Stephenson

University of Chicago Recurrent Pregnancy Loss Program, Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois; Department of Obstetrics and Gynecology, University of Illinois at Chicago, Chicago, Illinois

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Fertility and Sterility
Verified
Journal Article
Closed access
DMDana B. McQueen
Dana B. McQueen
LBLia A. Bernardi
Lia A. Bernardi
MSMary D. Stephenson
Mary D. Stephenson

1 March 2020 in Fertility and Sterility
Verified
Journal Article
Closed access
ADAllan C. Dong
Allan C. Dong
JMJessica Morgan
Jessica Morgan
MKMonica Kane
Monica Kane
ASAlex Stagnaro-Green
Alex Stagnaro-Green
MSMary D. Stephenson
Mary D. Stephenson

1 August 2014 in Fertility and Sterility
Verified
Journal Article
Closed access
CBChristina E. Boots
Christina E. Boots
LBLia A. Bernardi
Lia A. Bernardi
MSMary D. Stephenson
Mary D. Stephenson

7 May 2015 in Trials
Verified
Journal Article
Open access
PDF file
PJPaulien G de Jong
Paulien G de Jong
SQSiobhan Quenby
Siobhan Quenby
KBKitty Wm Bloemenkamp
Kitty Wm Bloemenkamp
BBBabette Am Braams-Lisman
Babette Am Braams-Lisman
JBJan Peter de Bruin
Jan Peter de Bruin
SMSaskia Middeldorp
Saskia Middeldorp
A large number of studies have shown an association between inherited thrombophilia and recurrent miscarriage. It has been hypothesized that anticoagulant therapy might reduce the number of miscarriages and stillbirth in these women. In the absence of randomized controlled trials evaluating the efficacy of anticoagulant therapy in women with inherited thrombophilia and recurrent miscarriage, a randomized trial with adequate power that addresses this question is needed. The objective of the ALIFE2 study is therefore to evaluate the efficacy of low-molecular-weight heparin (LMWH) in women with inherited thrombophilia and recurrent miscarriage, with live birth as the primary outcome. Randomized study of LMWH plus standard pregnancy surveillance versus standard pregnancy surveillance alone. Study population: pregnant women of less than 7 weeks’ gestation, and confirmed inherited thrombophilia with a history of 2 or more miscarriages or intra-uterine fetal deaths, or both. Setting: multi-center study in centers from the Dutch Consortium of Fertility studies; centers outside the Netherlands are currently preparing to participate. Intervention: LMWH enoxaparin 40 mg subcutaneously once daily started prior to 7 weeks gestational age plus standard pregnancy surveillance or standard pregnancy surveillance alone. Main study parameters/endpoints: the primary efficacy outcome is live birth. Secondary efficacy outcomes include adverse pregnancy outcomes, such as miscarriage, pre-eclampsia, syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP syndrome), fetal growth restriction, placental abruption, premature delivery and congenital malformations. Safety outcomes include bleeding episodes, thrombocytopenia and skin reactions. After an initial period of slow recruitment, the recruitment rate for the study has increased. Improved awareness of the study and acknowledgement of the need for evidence are thought to be contributing to the improved recruitment rates. We aim to increase the number of recruiting centers in order to increase enrollment into the ALIFE2 study. The study website can be accessed via www.ALIFE2study.org . The ALIFE2 study was registered on 19 March 2012 under registration number NTR3361

1 March 2017 in Fertility and Sterility
Verified
Journal Article
Closed access
MSMary D. Stephenson
Mary D. Stephenson
DMDana McQueen
Dana McQueen
MWMichelle Winter
Michelle Winter
HKHarvey J. Kliman
Harvey J. Kliman

5 October 2018 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
JRJ. F. W. Rikken
J. F. W. Rikken
CKC. R. Kowalik
C. R. Kowalik
MEM. H. Emanuel
M. H. Emanuel
MBM. Y. Bongers
M. Y. Bongers
TST. Spinder
T. Spinder
MGM. Goddijn
M. Goddijn
A septate uterus is a uterine anomaly that may affect reproductive outcome, and is associated with an increased risk for miscarriage, subfertility and preterm birth. Resection of the septum is subject of debate. There is no convincing evidence concerning its effectiveness and safety. This study aims to assess whether hysteroscopic septum resection improves reproductive outcome in women with a septate uterus. A multi-centre randomised controlled trial comparing hysteroscopic septum resection and expectant management in women with recurrent miscarriage or subfertility and diagnosed with a septate uterus. The primary outcome is live birth, defined as the birth of a living foetus beyond 24 weeks of gestational age. Secondary outcomes are ongoing pregnancy, clinical pregnancy, miscarriage and complications following hysteroscopic septum resection. The analysis will be performed according to the intention to treat principle. Kaplan-Meier curves will be constructed, estimating the cumulative probability of conception leading to live birth rate over time. Based on retrospective studies, we anticipate an improvement of the live birth rate from 35% without surgery to 70% with surgery. To demonstrate this difference, 68 women need to be randomised. Hysteroscopic septum resection is worldwide considered as a standard procedure in women with a septate uterus. Solid evidence for this recommendation is lacking and data from randomised trials is urgently needed. Dutch trial registry ( NTR1676 , 18th of February 2009).